PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of germs or bacteria called pneumococcus (pronounced new-mo-kock-us). For more information, see Section 1.

Along with PCV7, the vaccine it replaced, PCV13 is no longer available. PPSV23, known as Pneumovax 23, was approved by the FDA in 1983. It protects against 23 serotypes of pneumococcal bacteria.

Amid the growing importance of pneumococcal vaccination to prevent pneumonia during the change of seasons, confusion is ...

Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

Dominance of the pneumococcal vaccine category is a race between Merck ... Merck also sells an older shot called Pneumovax 23, which covers 23 serotypes but is based on an older polysaccharide ...

recorded $647 million with its rival conjugate vaccine Vaxneuvance and another $188 million from older, polysaccharide-based jab Pneumovax 23. Sanofi's new challenger is billed as a "next ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

report_id=VIT669 What factors are influencing the growth of the 23 Valent Pneumococcal Polysaccharide Vaccine Market over the forecast period? What is the competitive landscape in Vietnam 23 Valent ...

The STRIDE-10 trial compared the vaccine to pneumococcal vaccine, polyvalent [23-valent] (PPSV23) in those aged 50 years and above. The approval was further supported by outcomes from the Phase ...

Read all vaccine information available from your health care professional before receiving the vaccine. If you have any questions, ask your health care professional. This vaccine is injected into ...

A lack of vaccination against respiratory pathogens was commonly identified among US international travelers, indicating the need to improve vaccine uptake at pre-travel visits.

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...